tailieunhanh - Báo cáo y học: "Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT. | Gladman et al. Arthritis Research Therapy 2010 12 R113 http content 12 3 R113 RESEARCH ARTICLE Open Access Risklfactors for radiographic progression in psoriatic arthritis subanalysis of the randomized controlled trial ADEPT Dafna D Gladman1 Philip J Mease2 Ernest HS Choy3 Christopher T Ritchlin4 Renee J Perdok5 and Eric H Sasso 5 Abstract Introduction To identify independent predictors of radiographic progression in psoriatic arthritis PsA for patients treated with adalimumab or placebo in the Adalimumab Effectiveness in PsA Trial ADEPT . Methods Univariate analyses and multivariate linear regression analyses assessed risk for radiographic progression change in modified total Sharp score AmTSS from baseline to week 24 for C-reactive protein CRP and other baseline variables and for 24-week time-averaged CRP univariate analysis only . Subanalyses determined mean AmTSS for CRP subgroups. Analyses were post hoc with observed data. Results One hundred and forty-four adalimumab-treated patients and 152 placebo-treated patients were assessed. Mean CRP was 64 lower by week 2 with adalimumab and essentially unchanged with placebo. Univariate analyses indicated that elevated CRP at baseline and time-averaged CRP were strongly associated with radiographic progression for placebo-treated patients but not for adalimumab-treated patients. Multivariate analysis confirmed that elevated baseline CRP was the only strong independent risk factor for radiographic progression for CRP mg dl odds ratio 95 confidence interval to P . Adalimumab treatment reduced risk of progression approximately fivefold. The difference between mean AmTSS for adalimumab versus placebo was greatest for patients with baseline CRP mg dl vs. . Conclusions Systemic inflammation in PsA as indicated by elevated baseline CRP was the only strong independent predictor of radiographic progression. This association was observed predominantly for .